Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (CANF): 1 pipeline candidate · 1 upcoming catalyst · ~2 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
2.2 months
0% dilution
Lead: Phase 3
1 candidate
1 upcoming, next in ~714d
N/A
A transparent, data-derived signal for Can-Fite BioPharma Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.4M
Cash
$5.5M
Quarterly Burn
$8.9M
Runway
2.2 mo
Revenue
$405K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| piclidenoson | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$322K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 42,559 | $132K |
| citadel advisors llc | 34,150 | $106K |
| rhumbline advisers | 20,908 | $65K |
| citigroup inc | 5,482 | $17K |
| osaic holdings, inc. | 450 | $1K |
| fifth third bancorp | 150 | $465 |
| wells fargo & company/mn | 125 | $388 |
| hrt financial lp | 19,383 | $60 |
| activest wealth management | 10 | $31 |
| morgan stanley | 1 | $3 |
Showing top 10 of 12 institutional holders of Can-Fite BioPharma Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Can-Fite BioPharma Ltd.'s pipeline?
Can-Fite BioPharma Ltd. (CANF) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Can-Fite BioPharma Ltd.'s lead drug candidate?
Can-Fite BioPharma Ltd.'s most advanced tracked candidate is piclidenoson (Phase 3) for Lowe Syndrome; Plaque Psoriasis.
What is Can-Fite BioPharma Ltd.'s next catalyst?
Can-Fite BioPharma Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Pi" — expected June 1, 2028.
What is Can-Fite BioPharma Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Can-Fite BioPharma Ltd. has approximately 2.2 months of cash runway.
What is Can-Fite BioPharma Ltd.'s market capitalization?
Can-Fite BioPharma Ltd.'s market capitalization is approximately $6.4M.
Get the full picture on Can-Fite BioPharma Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.